Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer

Journal of Nuclear Medicine

Volumn 54, Issue 10, 2013, Pages 1697-1702

  Gemignani, Mary L ^a   Patil, Sujata ^a   Seshan, Venkatraman E ^a   Sampson, Michelle ^a   Humm, John L ^a   Lewis, Jason S ^a   Brogi, Edi ^a   Larson, Steven M ^a   Morrow, Monica ^a   Pandit Taskar, Neeta ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Estrogen receptor; Ligand; PET imaging

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORO 17BETA ESTRADIOL F 18; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRACER; UNCLASSIFIED DRUG; 16 FLUOROESTRADIOL; 16-FLUOROESTRADIOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LIGAND;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BODY MASS; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ESR1 GENE; ESR2 GENE; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEAN BODY WEIGHT; LYMPH NODE DISSECTION; MASTECTOMY; PARTIAL MASTECTOMY; PERIOPERATIVE PERIOD; PET-CT SCANNER; PGR GENE; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; TUMOR VOLUME; BREAST TUMOR; CLINICAL TRIAL; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PET IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TUMOR INVASION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DIAGNOSTIC USE;

BREAST CANCER; ESTROGEN RECEPTOR; LIGAND; PET IMAGING;

ADULT; AGED; BREAST NEOPLASMS; ESTRADIOL; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIGANDS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PERIOPERATIVE PERIOD; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ESTROGEN;

EID: 84891665561     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.113373     Document Type: Article

References (17)

1. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-784.
2. Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2005;103:164-173.
3. Castagnetta L, Traina A, Di Carlo A, et al. Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer? Br J Cancer. 1989;59:636-638.
4. van Netten JP, Armstrong JB, Carlyle SJ, et al. Cellular distribution patterns of estrogen receptor in human breast cancer. Eur J Cancer Clin Oncol. 1988;24: 1899-1901.
5. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T, Gomez F. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women: clinical correlation on 547 patients. Cancer. 1986;57:1171-1180.
6. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
7. Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011;17:4799-4805.
8. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526-1531.
9. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
10. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933-939.
11. 18Ffluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol. 2011;38:969-978.
12. 18F]fluoroestradiol-17 beta: the effect of reaction vessel on fluorine-18 resolubilization, product yield, and effective specific activity. Int J Rad Appl Instrum [A]. 1986;37:217-221.
13. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212-1221.
14. 18F- fluoroestradiol. J Nucl Med. 2008;49:367-374.
15. 18F]FES in ER positive breast cancer patients. J Pharm Pharm Sci. 2007;10(suppl):256s-265s.
16. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799.
17. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803.